Traws Pharma (TRAW) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on July 8, 2026, with voting and Q&A available online.

• Shareholders will vote on five key proposals, including director elections, plan amendments, auditor ratification, warrant share issuance, and potential adjournment.

• Proxy materials are distributed primarily electronically to expedite access and reduce costs.

Voting matters and shareholder proposals

• Seven directors are nominated for election to serve until the 2027 annual meeting.

• Proposal to amend the 2021 Incentive Compensation Plan to add 2,000,000 shares and make administrative changes.

• Ratification of KPMG LLP as independent auditor for fiscal year ending December 31, 2026.

• Approval for issuance of shares upon exercise of Series B and C Warrants under a Securities Purchase Agreement, in accordance with Nasdaq rules.

• Approval to adjourn the meeting if more votes are needed for any proposal.

Board of directors and corporate governance

• Board consists of seven members, with a mix of executive and independent directors.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and independent membership.

• Board leadership is separated between the CEO and Chairman roles to enhance oversight.

• Directors are encouraged to attend annual meetings and participate in self-evaluation processes.